Humanigen Inc (HGENQ)

[cowtown jay]

One thing to note is that Taran entered into an Asset Purchase Agreement with Humanigen, not a Buy Out, to include our pipeline products, the equity in one of our subsidiaries, and "certain causes of action." The main cause of action I want to see is the recall of our loaned shares. Humanigen will do nothing that would eliminate those shares until the short positions have been bought-in. That transaction could leave a substantial amount of cash on the balance sheet, following the resolution of the bankruptcy. It could certainly be enough in value to meet Nasdaq Listing Standards for a number of interested entities.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm

Such interested entities could include some of whom we may have engaged, such as Baudax/TeraImmune, Novavax, Gracell, and possibly AstraZeneca.

Our own interest, especially if Taran's purchased subsidiary survives as the Parent company of Humanigen, might best be served in Australia.

"Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development. Expanding the number of sites may accelerate enrollment. We anticipate seeing preliminary results from this study in the first half of 2023."

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx

Further, we now know the interim results of the PREACH-M study have been phenomenal.

"Humanigen and the Principal Investigator are assessing regulatory pathways that may enable
early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in
Australia, which could be expanded through Project Orbis10 to the United States and the United Kingdom."

https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-Europ-OYZCQ.pdf

I think things could come together for us very quickly now, and we could have positive regulatory and structural developments to report, to coincide with, and support, the recall of our loaned shares.